Brokerages Set Genmab A/S (NASDAQ:GMAB) Price Target at $45.20

Genmab A/S (NASDAQ:GMAB) has been assigned an average recommendation of “Moderate Buy” from the nine ratings firms that are currently covering the firm, Marketbeat.com reports. Three analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $45.20.

GMAB has been the subject of a number of recent analyst reports. BMO Capital Markets reissued an “outperform” rating and set a $48.00 price objective (up from $46.00) on shares of Genmab A/S in a research report on Friday, November 8th. Sanford C. Bernstein upgraded shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Friday, December 20th. Finally, HC Wainwright restated a “buy” rating and issued a $50.00 price objective on shares of Genmab A/S in a report on Thursday, January 23rd.

Institutional Trading of Genmab A/S

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Pitcairn Co. increased its stake in Genmab A/S by 70.1% during the 4th quarter. Pitcairn Co. now owns 18,541 shares of the company’s stock worth $387,000 after buying an additional 7,640 shares during the period. Trexquant Investment LP grew its stake in shares of Genmab A/S by 495.1% in the fourth quarter. Trexquant Investment LP now owns 379,936 shares of the company’s stock worth $7,929,000 after acquiring an additional 316,089 shares in the last quarter. OLD Mission Capital LLC purchased a new stake in shares of Genmab A/S during the fourth quarter worth $2,329,000. StoneX Group Inc. acquired a new stake in shares of Genmab A/S in the fourth quarter valued at $1,380,000. Finally, Franklin Resources Inc. boosted its holdings in Genmab A/S by 20.4% in the fourth quarter. Franklin Resources Inc. now owns 30,896 shares of the company’s stock valued at $645,000 after purchasing an additional 5,233 shares during the period. 7.07% of the stock is currently owned by hedge funds and other institutional investors.

Genmab A/S Price Performance

Shares of NASDAQ GMAB opened at $19.69 on Friday. The company has a market capitalization of $13.03 billion, a P/E ratio of 19.12, a P/E/G ratio of 0.54 and a beta of 0.96. The company has a 50 day simple moving average of $20.72 and a 200-day simple moving average of $23.24. Genmab A/S has a 1 year low of $18.64 and a 1 year high of $31.88.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings data on Wednesday, February 12th. The company reported $0.57 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.29. Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%. As a group, research analysts expect that Genmab A/S will post 1.25 EPS for the current year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.